Published 1 month ago • loading... • Updated 1 month ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Summary by Benzinga

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. ("Aardvark") (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the pricing of its initial public offering of 5,888,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares ar…

6 Articles

All

Left

Center

Right

Gilbert Sun News

+2 Reposted by 2 other sources

Center

Karman Announces Pricing of its Initial Public Offering

HUNTINGTON BEACH, Calif., Feb. 12, 2025 /PRNewswire/ -- Karman Holdings Inc. ("Karman" or the "Company"), a company specializing in the upfront design, testing, manufacturing, and sale of mission-critical systems for existing and emerging missile and defense, and space programs, today…

1 month ago

Read Full Article

Benzinga

Center

Aardvark Therapeutics Announces Pricing of Initial Public Offering

1 month ago·New York, United States

Read Full Article

Endpoints News

Hunger-suppressing biotech Aardvark raises $94M in IPO

Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday with a $94 million debut on the Nasdaq. The San Diego-based biotech joins fellow obesity drug ...

1 month ago

Read Full Article

stocktitan.net

Metabolic Disease Biotech Aardvark Launches $94M IPO, Backed by Wall Street Giants

Clinical-stage biotech prices IPO at $16/share, raising $94.2M to advance metabolic disease therapies. Major banks lead offering ahead of Nasdaq debut.

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year